U.S. Code · Título 42
Research centers for pathogens of pandemic concern
42 U.S.C. § 285f–5
Office of the Law Revision Counsel · release 119-142
Se muestra el texto operativo de la sección. Las notas estatutarias y el historial de enmiendas están en la fuente oficial.
In general
The Director of the Institute, in collaboration, as appropriate, with the directors of applicable institutes, centers, and divisions of the National Institutes of Health, the Assistant Secretary for Preparedness and Response, and the Director of the Biomedical Advanced Research and Development Authority, shall establish or continue a multidisciplinary research program to advance the discovery and preclinical development of medical products for priority virus families and other viral pathogens with a significant potential to cause a pandemic, through support for research centers.
Uses of funds
The Director of the Institute shall award funding through grants, contracts, or cooperative agreements to public or private entities to provide support for research centers described in subsection (a) for the purpose of—
Coordination
The Director of the Institute shall, as appropriate, provide for the coordination of activities among the centers described in subsection (a), including through—
Priority
In awarding funding through grants, contracts, or cooperative agreements under subsection (a), the Director of the Institute shall, as appropriate, give priority to applicants with existing frameworks and partnerships, as applicable, to support the advancement of such research.
Collaboration
The Director of the Institute shall—
Supplement, not supplant
Any support received by a center described in subsection (a) under this section shall be used to supplement, and not supplant, other public or private support for activities authorized to be supported.
(July 1, 1944, ch. 373, title IV, § 447D, as added Pub. L. 117–328, div. FF, title II, § 2301, Dec. 29, 2022, 136 Stat. 5756.)